AUTHORS
Zi-Qi Huo, Qi Chen2, Qiu-Sha Huang, MD3, Zhuo-Yu An, MD4, Peng Zhao5, Hai-Xia Fu, MD6, Jianliu Wang7, Xiaojun Huang, MD,PhD8, Xiaohui Zhang, MD9
AFFILIATIONS
1 Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
2 Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
3 Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
4 Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
5 Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
6 Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
7 Department of Obstetrics and Gynecology, Peking University People's Hospital, Beijing, China
8 Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
9 Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, China
ABSTRACT
Introduction
Immune thrombocytopenia (ITP) is characterized by both immune-mediated platelet clearance and impaired platelet production. ITP is a clinically relevant contributor to severe maternal hemorrhage. During pregnancy, patients with ITP experience disease-associated immune dysregulation together with marked physiological increases in 17β-estradiol levels, whereas platelet counts may decrease further, particularly during late gestation, complicating the management of peripartum bleeding. Efficient platelet production requires mitochondrial homeostasis and cytoskeletal remodeling. Building on our previous work, we examined whether MST1 contributes to defective proplatelet formation in ITP during pregnancy by mediating mitochondrial dysfunction and dysregulated cytoskeletal remodeling.
Methods
Mouse models of healthy pregnancy, ITP and ITP in pregnancy were established. Proplatelet formation was evaluated by phase-contrast microscopy, and the proportion of megakaryocytes with β1-tubulin staining and the expression level of filamentous actin (F-actin) were evaluated by confocal microscopy. The ultrastructure of the demarcation membrane system (DMS) was assessed via transmission electron microscopy. Megakaryocytes generated from CD34? cells derived from ITP patients were treated with increasing concentrations of 17β-estradiol. Flow cytometry was used to quantify apoptosis, intracellular reactive oxygen species (ROS), and the mitochondrial membrane potential. The basal mitochondrial oxygen consumption rate (OCR) was assessed via extracellular flux analysis. Western blotting was used to assess protein levels in the MST1-FOXO1 and MST1-YAP1 pathways. Megakaryocytes exposed to elevated 17β-estradiol levels were transfected with MST1-targeting small interfering RNA (siRNA), after which mitochondrial function, cytoskeletal organization, and proplatelet formation were reevaluated.
Results
Transmission electron microscopy revealed marked disorganization of the DMS. Confocal microscopy and immunofluorescence analysis demonstrated a significant reduction in β1-tubulin staining after exposure to high concentrations of 17β-estradiol. Consistent with these changes, reduced F-actin staining and decreased F-actin levels in megakaryocytes were also observed following exposure to 17β-estradiol, supporting impaired actin and microtubule remodeling. These cytoskeletal abnormalities were accompanied by fewer proplatelet-forming megakaryocytes and impaired proplatelet extension.
Exposure to high concentrations of 17β-estradiol also resulted in significant mitochondrial dysfunction. A high concentration of 17β-estradiol was associated with a significant decrease in the mitochondrial membrane potential. Mitochondrial depolarization was most pronounced at a 17β-estradiol concentration of 100 nM. A high concentration of 17β-estradiol also led to an increase in the intracellular levels of ROS. Furthermore, 17β-estradiol treatment decreased the OCR in megakaryocytes, as shown by extracellular flux analysis, suggesting impaired mitochondrial respiratory function. These alterations coincided with increased megakaryocyte apoptosis, which was most prominent at the 17β-estradiol concentration of 100 nM. Consistent with the in vitro findings, megakaryocytes from pregnant mice with ITP presented comparable abnormalities, including disorganized DMS architecture, a reduced proportion of megakaryocytes positive for β1-tubulin staining, decreased F-actin levels and impaired mitochondrial function. Moreover, immunofluorescence staining demonstrated reduced contact between megakaryocytes and bone marrow sinusoids in pregnant mice with ITP.
Elevated 17β-estradiol exposure induced activation of the MST1-FOXO1 and MST1-YAP1 axes. Silencing MST1 using siRNA altered FOXO1 and YAP1 protein expression and partially reversed the detrimental effects of elevated 17β-estradiol on megakaryocyte function. More specifically, MST1 knockdown enhanced proplatelet formation, increased the proportion of β1-tubulin-positive megakaryocytes, restored F-actin levels, improved the OCR and reduced intracellular ROS accumulation.
Conclusions
Our findings identify MST1 as a critical regulator of mitochondrial dysfunction and dysregulated cytoskeletal remodeling, thereby leading to defective proplatelet formation in ITP during pregnancy. Collectively, these findings support MST1 as a potential therapeutic target for the restoration of thrombopoiesis.
DISCLOSURES
Zi-Qi Huo: No relevant conflicts of interest to declare.